title: Kaposi's sarcoma in renal-transplant recipients: experience at the Catholic University in Rome, 1988-1996.
abstract: BACKGROUND
  The incidence of Kaposi's sarcoma (KS) in patients transplanted at the Organ Transplant Center of Catholic University in Rome appears to have increased in recent years.
  
  
  OBJECTIVE
  To describe the clinical characteristics of KS in a group of transplant recipients.
  
  
  METHODS
  Over 8 years, a total of 302 renal-transplant recipients were followed. When KS was suspected, histology and staging procedures were performed.
  
  
  RESULTS
  Ten cases of KS have been diagnosed (8 males, 2 females; age 46.4 +/- 9.4 years); 4 of them were on triple therapy. All the patients were HIV-1 seronegative. The onset of KS occurred 3 months to 4 years after transplantation (21.1 +/- 17.6 months). The disease was limited to the skin in 6 cases and involved internal organs in the remaining 4. Four patients experienced complete remission of the disease following reduction of the immunosuppressive therapy.
  
  
  CONCLUSIONS
  The high incidence of KS in this population (2.98%), as compared to that reported in other transplant patient groups, suggests that, besides viral infection, genetic predisposition may play a pathogenetic role. However, immunosuppression is the leading factor in transplant patients.
authors.affiliation: Istituto di Clinica Dermatologica, Università Cattolica Sacro Cuore, Roma, Italia.
authors.forename: I
authors.initials: I
authors.lastname: Lesnoni La Parola
authors.forename: C
authors.initials: C
authors.lastname: Masini
authors.forename: G
authors.initials: G
authors.lastname: Nanni
authors.forename: A
authors.initials: A
authors.lastname: Diociaiuti
authors.forename: N
authors.initials: N
authors.lastname: Panocchia
authors.forename: D
authors.initials: D
authors.lastname: Cerimele
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D018023:HIV Seronegativity; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000706:statistics & numerical data; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D012384:Rome / Q000453:epidemiology; D012514:Sarcoma, Kaposi / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D014777:Virus Diseases / Q000150:complications
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone